Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$69.10
-0.6%
$71.81
$60.56
$82.49
$8.46B0.871.74 million shs1.18 million shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$36.21
-3.1%
$33.84
$27.66
$121.06
$4.82B1.191.49 million shs1.19 million shs
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
$199.92
$198.62
$23.27
$199.98
$9.56B-0.49913,102 shsN/A
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$104.90
+0.1%
$87.55
$18.51
$105.30
$8.51B0.241.72 million shs2.96 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Henry Schein, Inc. stock logo
HSIC
Henry Schein
-0.58%-5.88%-2.85%+6.75%-2.98%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-3.10%+0.78%+8.41%+18.14%-55.50%
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
0.00%0.00%0.00%0.00%0.00%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
+0.11%+0.07%+15.38%+78.04%+359.28%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Henry Schein, Inc. stock logo
HSIC
Henry Schein
4.2617 of 5 stars
3.23.00.03.42.01.71.9
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
1.8294 of 5 stars
3.61.00.00.02.51.70.0
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
2.3983 of 5 stars
2.15.00.00.02.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Henry Schein, Inc. stock logo
HSIC
Henry Schein
2.36
Hold$78.3613.41% Upside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10
Buy$136.50276.97% Upside
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
0.00
N/AN/AN/A
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
2.15
Hold$109.003.91% Upside

Current Analyst Ratings Breakdown

Latest RXDX, PCVX, HSIC, and VRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/14/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$75.00
7/14/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/14/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Neutral$82.00 ➝ $72.00
7/14/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$90.00 ➝ $107.00
7/10/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/10/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/10/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/10/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$138.00 ➝ $107.00
7/10/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/9/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
7/9/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetIn-Line ➝ In-Line$72.00 ➝ $78.00
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$12.67B0.66$7.29 per share9.48$32.33 per share2.14
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$26.52 per shareN/A
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
$6.81M1,403.55N/AN/A$16.12 per share12.40
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$118.54M71.75N/AN/A$2.56 per share40.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$390M$3.2021.5913.762.253.21%14.87%5.82%8/5/2025 (Estimated)
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$463.93M-$3.99N/AN/AN/AN/A-17.12%-16.26%8/5/2025 (Estimated)
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
-$141.75M-$3.52N/AN/AN/A-3,768.76%-33.50%-29.59%N/A
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$173.42M-$2.00N/A3,496.67N/AN/A-69.65%-28.00%8/6/2025 (Estimated)

Latest RXDX, PCVX, HSIC, and VRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$0.39N/AN/AN/A$68.24 millionN/A
8/5/2025Q2 2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$1.19N/AN/AN/A$3.22 billionN/A
8/5/2025Q2 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.12N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.02-$1.04-$0.02-$1.04N/AN/A
5/5/2025Q1 2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$1.11$1.15+$0.04$0.88$3.24 billion$3.17 billion
4/29/2025Q1 2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Henry Schein, Inc. stock logo
HSIC
Henry Schein
N/AN/AN/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
N/AN/AN/AN/AN/A
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Henry Schein, Inc. stock logo
HSIC
Henry Schein
0.50
1.38
0.75
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
17.70
17.70
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
0.04
37.56
37.56
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
1.07
8.86
8.73

Institutional Ownership

CompanyInstitutional Ownership
Henry Schein, Inc. stock logo
HSIC
Henry Schein
96.62%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
92.66%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
85.88%
CompanyEmployeesShares OutstandingFree FloatOptionable
Henry Schein, Inc. stock logo
HSIC
Henry Schein
25,000121.72 million120.41 millionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160129.00 million125.01 millionOptionable
Prometheus Biosciences, Inc. stock logo
RXDX
Prometheus Biosciences
9747.81 million46.19 millionNot Optionable
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
3081.08 million81.05 millionOptionable

Recent News About These Companies

Pharmaceutical Stocks To Research - July 14th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Henry Schein stock logo

Henry Schein NASDAQ:HSIC

$69.10 -0.40 (-0.58%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$69.10 0.00 (0.00%)
As of 07/18/2025 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$36.21 -1.16 (-3.10%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$36.25 +0.04 (+0.11%)
As of 07/18/2025 04:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Prometheus Biosciences stock logo

Prometheus Biosciences NASDAQ:RXDX

Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.

Verona Pharma PLC American Depositary Share stock logo

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$104.90 +0.12 (+0.11%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$104.86 -0.05 (-0.04%)
As of 07/18/2025 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.